Head and neck cancers
Open
Phase 2
Please note - the trial team have asked us to base this summary on the information available on https://clinicaltrials.gov(link is external). There is less detail than we would usually include and it hasn't been checked by them.
This trial is comparing BT113 and pembrolizumab to pembrolizumab alone, for head and neck cancer.
It is for people who have cancer that:
has come back after other treatment or has recently spread to another part of the body
cannot be removed with an operation
is linked to a virus called human papillomavirus type16 (HPV16)
has lots of a protein called PD-L1 (is PD-L1 positive)
Recruitment start: 7 January 2021
Recruitment end: 31 March 2028
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
We haven't been able to get this information.
BioNTech SE
This summary is based on information provided on https://clinicaltrials.gov(link is external). It has not been checked by the team running the trial.
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)(link is external) National Library of Medicine website Accessed September 2024
There is more information about the side effects people have had so far in the reference below.
155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT(link is external) K. Klinghammer and others ESMO Immuno-Oncology and Technology, 2022. Volume 16, supplement 1100267.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Last reviewed: 17 September 2024
CRUK internal database number: 19915
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
